For aqueous injectable manufacturing, the critical path begins with powder characterisation rather than vessel charging: the received material is passed through a 0.5 mm stainless-steel sieve, assayed for potency, loss on drying, and dispersibility in Water for Injections at 25 °C. A 10.0 mg/mL target solution requires 1.0% w/v active material, equivalent to 5.00 kg per 500 L batch; overage beyond the approved dossier is not permitted unless stability data under VICH GL3 justify it. The bulk solution is compounded in a SS316L jacketed vessel with bottom-mounted agitation and nitrogen overlay, and pH is adjusted with 0.1 M hydrochloric acid or sodium hydroxide into the formulation-specific stability range, commonly 4.5–7.5. Sterilisation by moist heat is preferred when the active substance is thermotolerant, using a validated autoclave cycle at 121 °C for 15 min with an F0 ≥15 minutes according to Ph.Eur. 5.1.1; where thermolability is confirmed by forced degradation, aseptic filtration through a 0.22 µm polyethersulphone membrane with 0.45 µm pre-filtration at a maximum differential pressure of 1.0 bar is substituted. The finished injectable is tested for sterility by USP <71> and Ph.Eur. 2.6.1, with no growth after 14 days; bacterial endotoxin is controlled below 0.25 EU/mL if the product is intended for intravenous administration, while intramuscular and subcutaneous presentations may use a wider limit only if justified in the dossier. Filling is performed on a rotary piston pump inside a Grade A laminar-airflow zone with Grade B background; fill-volume tolerances are ±5.0% for volumes up to 50 mL and ±3.0% for volumes above 50 mL. Primary containers are Type I or Type II borosilicate vials of 20 mL, 50 mL, 100 mL, and 250 mL, with chlorobutyl stoppers and flip-off aluminium seals. Terminal product types are injectable solutions for intravenous, intramuscular, and subcutaneous administration.

What Limits Wet Granulation Throughput for High-Dose Powders in Compressed Tablets?

Wet granulation is selected when direct compression trials with the supplied powder show segregation tendency, capping at compression forces above 15 kN, or insufficient flow through a 10 mm gravity-feed shoe. At 30–65% w/w active loading, the formulation contains microcrystalline cellulose 15–30% w/w, lactose monohydrate 10–25% w/w, povidone K30 3–5% w/w, crospovidone 2–4% w/w, colloidal anhydrous silica 0.5% w/w, and magnesium stearate 0.5–1.0% w/w. The binder solution at 5–10% w/w in purified water is sprayed into a high-shear granulator with a 3-blade impeller and side chopper; impeller speed 200–400 rpm, chopper speed 1,500–3,000 rpm, and post-binder granulation time 3–8 min are adjusted to produce granules with D50 120–180 µm.

Drying in a fluid-bed dryer is run with inlet-air temperature 60–70 °C and product temperature not above 40 °C to limit binder migration and potential Maillard side reactions when lactose is present; residual moisture after drying is held at 1.5–3.0%. Dried granules are milled through a 0.8 mm or 1.0 mm screen, with oversized granules recycled at no more than 20% of batch mass to avoid bulk-density drift and work-hardening. Compression is performed on a 16-station rotary tablet press with D-type tooling, pre-compression force 5–10 kN, main compression force 12–25 kN, turret speed 20–40 rpm, target hardness 80–120 N, and friability below 1.0% after 100 rotations per Ph.Eur. 2.9.7. Dissolution is tested under USP <711> Apparatus II in 900 mL purified water at 37 °C and 50–75 rpm; the acceptance criterion is dossier-specific, but immediate-release formulations typically require not less than 75% release in 45 min. Disintegration is controlled under Ph.Eur. 2.9.1 with a limit of not more than 15 min in water at 37 °C for conventional tablets. The principal production bottleneck is post-compression capping when granule moisture falls below 1.0% or when magnesium stearate is over-blended beyond 5 min at 25 rpm, which can delay dissolution by more than 10 min. Regulatory controls for finished tablets include content uniformity under USP <905> with acceptance value AV≤15.0, elemental impurities under ICH Q3D, and stability under VICH GL3. Finished product types include 1 g, 5 g, and 20 g veterinary oral tablets packed in high-density polyethylene jars or aluminium/PVC blisters.

Intermittent motion dosator capsule machines impose a narrow window for granulate compressibility, and lot-to-lot particle-size distribution of the supplied powder must be controlled before encapsulation begins. The production route for capsules is dry granulation rather than direct filling because the as-received fine fraction creates dust loss, poor tamping weight control, and unacceptable capsule-to-capsule variability. At 20–45% w/w active loading, the blend consists of lactose monohydrate 30–50% w/w, microcrystalline cellulose 15–25% w/w, croscarmellose sodium 2–4% w/w, and magnesium stearate 0.5–1.0% w/w. Roller compaction is performed with roll force 8–12 kN/cm, roll gap 2 mm, and screen aperture 0.8 mm; the granulate is classified to D90 250 µm and fines below 15% through a 75 µm sieve. Encapsulation runs at 50,000–120,000 capsules/h on a dosator machine, with fill-weight checks every 15 min and rejection limits of ±3.0% from target.

The main stability boundary is shell moisture. Hard gelatin capsules are filled only when shell moisture is 13–16%; hydroxypropyl methylcellulose capsules are used when storage exceeds 30 °C and 65% RH or when gelatin cross-linking is observed. Finished capsule strengths include 250 mg, 500 mg, and 1 g. Quality testing follows Ph.Eur. 2.9.5 for uniformity of mass, USP <905> for content uniformity, USP <711> for dissolution, and Ph.Eur. 2.9.1 for disintegration; hard-shell identity and gel strength are controlled under Ph.Eur. 5.1.4. A production-scale failure observed in dosator filling is the accumulation of hydrophobic lubricant on the tamping pin after approximately 8 h continuous operation, causing the fill-weight coefficient of variation to exceed 5.0%; pins are then polished with anhydrous ethanol and the run is restarted. If the supplied powder exceeds 2.0% loss on drying or storage relative humidity exceeds 60%, pre-drying at 40 °C for 4 h is evaluated before granulation. Finished products are hard gelatin and HPMC capsules for oral administration in target veterinary species.

Carryover Control in Medicated Premix Lines When a 10 g/kg Preblend Is Diluted to 200 mg/kg

In a double-shaft paddle mixer charged to 60–80% of working capacity, the concentrated API is incorporated by sequential dilution because direct addition of a low-dose powder to a 1 ton feed batch cannot reliably achieve a coefficient of variation below 5.0%. A first preblend at 10–50 g/kg, equivalent to 1.0–5.0% w/w, is prepared with ground limestone or wheat middlings as carrier, then diluted 1:10 and again 1:10 to reach a final feed concentration of 100–400 mg/kg (0.01–0.04% w/w). Mixing continues for 8–12 min after the last ingredient addition, and the batch is released only when a tracer study using ferrous sulphate or riboflavin demonstrates CV<5.0%. Compliance for medicated feed is governed by EU Regulation 2019/4, FDA 21 CFR 225 and 226, and GMP+ or FAMI-QS certification where feed assurance is required.

Carryover control is the most demanding technical boundary. After high-potency batches, the changeover procedure includes air-jet cleaning of mixer shafts, vacuum recovery from seals and dead zones, and a flush batch of 100–250 kg ground maize or wheat bran. Swab samples from the discharge gate are assayed by HPLC; the limit for the following batch is 1 mg/kg or the validated detection limit, whichever is lower. When published carrier adsorption data for this specific API are limited, a 50 kg pilot-scale batch is run to establish recovery and degradation before commercial batches are committed. Finished product types include 5 kg and 20 kg premix bags, 25 kg paper/PE laminated sacks for pelleted feed top-dress, and bulk complete feed pellets of 3–5 mm diameter produced at post-conditioning temperatures not exceeding 80 °C to avoid thermal loss of the active material. The limiting process variable is not mixer speed but the residual product left in the 0.5–1.0 m discharge chute; when the chute is not dismantled, carryover values in the subsequent non-medicated batch can exceed 5 mg/kg.

If the API Is Formulated into Soluble Powders, Water Quality and Chelation Determine Redissolution Efficiency

When drinking-water medication is the required route, the powder formulation must tolerate on-farm water from pH 6.0 to 9.0 and total hardness from 50 ppm to 300 ppm CaCO₃. A dry blend containing 5–25% w/w active powder is prepared with dextrose monohydrate or sucrose as carrier, sodium bicarbonate 1–3% w/w as alkalising agent, citric acid 1–2% w/w as buffering agent, and disodium edetate 0.1–0.5% w/w as chelating agent for calcium and iron. Mixing is performed in a V-blender with an intensifier bar at 60–70% fill for 15–20 min; the discharged powder must have loss on drying below 2.0% and pass through a 0.5 mm sieve without residue. Filling into aluminium/polyethylene foil-laminate sachets is executed at 20–25 °C and 40–50% RH; humidity below 35% RH increases static charge above 1 kV and causes sealing through a dust film.

Compliance for soluble powders and oral solutions includes stability under VICH GL3, residual solvents under VICH GL18, and microbial quality under Ph.Eur. 5.1.4; where commercial manufacture is performed in the EU or US, the facility operates under EU GMP Part I or 21 CFR 210/211. The redissolution test is specific: 10 g of powder is added to 1 L of tap water at 20 °C and stirred at 50 rpm; the solution is inspected after 10 min for undissolved particles, sediment, and foam. If carbonate hardness exceeds 150 ppm CaCO₃, the formulation is adjusted with an increased chelator ratio or the label instructs pre-boiling and cooling of the drinking water. Finished product types include 100 g, 500 g, and 1 kg foil sachets for inline medication, and 5 L oral solution packs for direct metering pumps. The critical production failure observed on vertical form-fill-seal lines is dust contamination of the seal area; this is controlled by maintaining packaging-hall humidity above 40% RH and by installing ionising bars at the fill chute.

Granulating for Dose Uniformity in Multi-Active Top-Dress Pellets

Fluid-bed rotor granulation is selected when the API is incorporated into pelleted top-dress formulations for individual animal dosing. The powder is loaded at 10–50% w/w of the dry microcrystalline cellulose core mass, and a binder solution of hydroxypropyl methylcellulose 3–5% w/w in purified water is sprayed through a 1.2 mm two-fluid nozzle. In a fluid-bed rotor such as a Glatt GPCG 5.1 or equivalent, the inlet-air temperature is 50–70 °C, spray rate 5–20 g/min, atomising pressure 1.5–2.5 bar, rotor speed 200–500 rpm, and final moisture below 2.0%. Granulation time typically ranges from 20 min to 45 min; nozzle blockage occurs when binder viscosity exceeds 150 mPa·s at 25 °C or when the liquid line is not purged within 5 min of stopping spray. Laser-diffraction particle sizing is performed after each run; the target granule D50 is 350–700 µm, with fines below 150 µm not exceeding 10% and oversized granules above 1,400 µm not exceeding 5%.

Content uniformity on 10 units is tested at the beginning, middle, and end of the discharge cycle using USP <905>, with acceptance value AV≤15.0. Compliance for granular veterinary products includes Ph.Eur. 2.9.7 for friability, Ph.Eur. 2.9.3 for dissolution if the granules are later coated, and VICH GL3 for stability. Finished product types consist of 1 g, 5 g, and 10 g unit-dose cups, 1 kg tubs for stock administration, and bulk granulate that can be compressed or encapsulated in subsequent operations. A production-scale bottleneck is moisture migration from the wet core to the filter bag during the first 10 min of drying; exhaust humidity must be monitored and the bed shaken every 3–5 min to prevent channelling and black speck formation from overheated fines. Published data for this specific API in multi-active pellets are limited; therefore any claim of zero interaction with other actives in the same granulate must be supported by pilot-scale binary-mixture forced degradation studies. Without those studies, the API should be separated from reducing sugars and high-surface-area silicates during long-term storage.